IMA - Ikena Oncology, Inc.

5.84
-0.200   -3.425%

Share volume: 5,223
Last Updated: 03-06-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.17%

PREVIOUS CLOSE
CHG
CHG%
$6.04
-0.20
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
37%
Profitability 43%
Dept financing 20%
Liquidity 58%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-4.42%
1 Month
-20.65%
3 Months
-10.70%
6 Months
-37.14%
1 Year
314.18%
2 Year
265.00%
Key data
Stock price
$5.84
P/E Ratio 
0.00
DAY RANGE
$5.84 - $6.01
EPS 
-$3.35
52 WEEK RANGE
$0.97 - $18.00
52 WEEK CHANGE
$314.18
MARKET CAP 
32.775 M
YIELD 
N/A
SHARES OUTSTANDING 
11.182 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
0.64
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$11,089
AVERAGE 30 VOLUME 
$33,325
Company detail
CEO: Mark Manfredi
Region: US
Website: ikenaoncology.com
Employees: 70
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Ikena Oncology, Inc. focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway.

Recent news